All In Biotech

Free tool

FAERS Monitor: Betoptic

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019270 or its brand name (Betoptic, Betaxolol Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

325

Serious

301

93% of reports

Hospitalization

219

Death reported

37

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fall58
  • dyspnoea47
  • drug ineffective37
  • asthma33
  • nausea32
  • pain31
  • limb injury30
  • wound30
  • cardiac failure congestive29
  • fatigue29
  • haemorrhage29
  • transient ischaemic attack29
  • diarrhoea28
  • dizziness28
  • vomiting26

Reports by year received

View as table
YearReports
20042
20058
20065
20076
20084
20096
20106
20116
20127
20133
20145
20156
201610
201714
201831
201945
202019
202111
202233
202327
202433
202522
202616

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,834 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
limb injurySignal3071.650.92,017
woundSignal3069.549.41,959
transient ischaemic attackSignal2955.739.31,504
cardiac failure congestiveSignal2923.416.5601
asthmaSignal3318.913.7545
haemorrhageSignal2918.012.7450
fallSignal5811.38.9542
dyspnoeaSignal475.44.1167
dizzinessSignal283.62.552
vomitingSignal263.62.547
painSignal313.32.348
diarrhoeaSignal282.82.032
nauseaSignal322.61.932
fatigueSignal292.41.723
drug ineffective371.81.314

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.